Barrington Believes Henry Schein (HSIC) Won’t Stop Here


In a report released today, Michael Petusky from Barrington maintained a Buy rating on Henry Schein (HSIC), with a price target of $96. The company’s shares opened today at $87.33, close to its 52-week high of $90.52.

Petusky said:

“We are currently modeling $4.10. It is important to note that management’s adjusted EPS guidance does not include any impact from the upcoming animal health spin-off and merger, which is expected to occur around year end. In addition, the guidance does not factor in any future M&A activity.”

According to TipRanks.com, Petusky is a 5-star analyst with an average return of 14.2% and a 62.4% success rate. Petusky covers the Services sector, focusing on stocks such as US Physical Therapy, Tivity Health Inc, and BioScrip Inc.

Henry Schein has an analyst consensus of Hold, with a price target consensus of $83.40, which is a -4.5% downside from current levels. In a report released yesterday, Piper Jaffray also maintained a Buy rating on the stock with a $90 price target.

.

See today’s analyst top recommended stocks >>

Based on Henry Schein’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $121 million. In comparison, last year the company had a net profit of $138 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts